![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Vento Sandro Cainelli Francesca Temesgen Zelalem
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.17, Iss.11, 2008-11, pp. : 1635-1639
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
New horizons in hepatitis C therapy
Inpharma, Vol. 1, Iss. 1265, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Future trends in hepatitis C therapy
By Cornberg Markus Manns Michael
Future Virology, Vol. 1, Iss. 1, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antiviral therapy reduces HRQOL in patients with hepatitis C
Reactions Weekly, Vol. 1, Iss. 1100, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
`Pegasys' hot on the heels of standard hepatitis C therapy
Inpharma, Vol. 1, Iss. 1295, 2001-01 ,pp. :